ABAssia Bensalem

Assia Bensalem

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Assia Bensalem has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Milder Than Expected: Real-World Endocrine Toxicity Profile of Immune Checkpoint Inhibitors in Eastern Algeria

    by Shem Bensalem, Abdelaziz Ammari, Assia Bensalem, Amina Khodja

    The recent introduction of immune checkpoint inhibitors (ICIs) in Algeria in late 2024 has transformed the therapeutic landscape for multiple malignancies. While endocrine immune-related adverse events (irAEs) are well-documented globally, real-world data concerning their clinical presentation and severity in the Algerian population remain scarce. This study aims to report the initial experience of endocrine toxicity management following the introduction of PD-1 and PD-L1 inhibitors across a broad spectrum of cancers. We conducted an observational, real-world analysis within a medical oncology department in Eastern Algeria, enrolling patients initiated on ICI therapy since late 2024. The cohort comprised 84 patients distributed across various tumor types and regimens: 60 received pembrolizumab (23 triple-negative breast cancer, 17 non-small cell lung cancer, 9 renal cell carcinoma [RCC], 8 melanoma, 3 gastric cancer); 19 received nivolumab (5 pancreatic cancer, 4 urothelial carcinoma, 3 head and neck cancer, 5 RCC, 2 gastric cancer); 3 received avelumab (RCC); and 2 received atezolizumab (hepatocellular carcinoma). While various potential toxicities were monitored, particular attention was dedicated to endocrine side effects, which mandated the active involvement of endocrinologists in this surveillance framework. All toxicities were graded according to CTCAE v5.0 criteria. Endocrine irAEs were observed within the cohort, with dysthyroidism representing the most frequent manifestation and the primary driver for endocrinological referral. Strikingly, the clinical severity of these endocrine toxicities was notably lower than the profiles typically reported in the international literature. The majority of events were low-grade (CTCAE Grade 1-2), allowing for symptomatic hormonal substitution without necessitating ICI discontinuation. No high-grade (Grade 3-4) endocrinopathies, such as fulminant hypophysitis or adrenal crisis, were documented in this preliminary cohort. In this initial real-world experience from Eastern Algeria, the use of pembrolizumab, nivolumab, avelumab, and atezolizumab across various localizations demonstrates a manageable endocrine safety profile, with toxicities manifesting at a lesser severity than expected. These findings support a favorable risk-benefit ratio; however, the specific impact on thyroid function underscores that ongoing multidisciplinary surveillance—actively integrating endocrinologists—remains imperative to ensure prompt management and treatment continuity.

  • L´apport des abords vasculaires centraux dans la prise en charge des patients recevant une chimiothérapie pour des tumeurs malignes non hématologiques: PICC line versus chambres implantables

    by Ouassila Bendjaballah, Sofiane Chioukh, Assia Bensalem, Hichem Makhloufi, Atika Karoune, Abdelhak Lekhal, Rima Mouellef

    Introduction: les cathéters centraux à insertion périphérique (PICC) et les chambres implantables (Ports) sont utilisés pour la chimiothérapie. Cette étude vise à comparer leur morbi-mortalité et l'incidence des complications. Méthodes: une étude prospective, comparative randomisée et monocentrique, avec un suivi de 6 mois, a inclus des patients adultes atteints de tumeurs non hématologiques, éligibles à une chimiothérapie (intention palliative, curative ou adjuvante). Les critères d'évaluation principaux étaient la fréquence des événements indésirables (mineurs/majeurs), l'impact sur la qualité de vie (EORTC QLQ-C30) et le coût médico-économique. Résultats: sur 206 patients randomisés, 192 ont été analysés (Port: 102; PICC: 90). L'incidence globale des complications était de 12,5% (n=24). Les complications majeures étaient significativement plus fréquentes avec les PICC (17,8%; 16/90) qu'avec les Ports (4,9%; 5/102), avec un risque relatif de 3,6 (IC95% 1,3-9,9; p=0,041). Pour une chimiothérapie de moins de 6 mois, le coût total moyen était significativement plus élevé pour les Ports (160 123,41 DA) que pour les PICC (43 259,69 DA) (p<0,001). Aucune différence significative n'a été observée sur la qualité de vie globale, avec une tendance modeste en faveur des Ports pour la santé globale et la douleur à trois mois. Conclusion: les ports, bien que plus coûteux, sont associés à un risque significativement plus faible de complications majeures. Ils pourraient être préférés comme accès sûr et efficace pour les chimiothérapies de longue durée. Le choix optimal doit intégrer la durée du traitement, le profil de risque du patient et les contraintes économiques.

  • Open Access

    Influenza Vaccination for Cancer Patients: An Algerian Single Center Experience

    by Assia Bensalem, Meryem Boudjerda, Nadjet Lachter, Rym Sebia, Abdellaziz Ammari, Sihem Bensalem, Djamel Bensaad, Rym Mouallef, Khouloud Brahimi, Asma Seghir, et al.

    Background: Viral infections are very severe infections and can be responsible for death, as is the case with influenza infection; which during a short period of spread can cause significant deaths in the general population, and in immunocompromised patients in particular; as is the case with cancer patients; weakened by the disease and viral infection too. Patients with cancer are at high risk of severe infections complications. Among people with immunosuppression due to chemotherapy, corticosteroid treatment, or immunotherapy, high rates of influenza infection and related complications are frequently observed. In Algeria, the influenza vaccine is recommended for people aged 65 and over, as well as for those with chronic medical conditions who are at high risk of complications. It is offered by the government free of charge to elderly and other risk groups and distributed through general hospitals and pharmacists Material and methods: The medical oncology department of the Establishment DIDOUCHE Mourad, Constantine, launched a vaccination campaign for eligible patients, during the vaccination campaign initiated by the Algerian Ministry of Health during seasonal infection from October to December, each year. During two (02) months of medical oncology consultations (November 2024 to December 2024), 2047 patients were consulted and 264 patients were concerned by the vaccination. The findings emphasize the crucial role of healthcare professionals in advocating for influenza vaccination among cancer patients and the need for collaboration with health authorities to improve vaccination coverage Results: For a total of 2047 patients consulted (whose 43 (2,10 %) were already vaccinated), 892 (43.57%) patients refused the idea of vaccination. 784 (38.29%) patients did not want to comment yet at the time of the consultation and preferred to continue their treatments, 53 (2.58%) were postponed for bone marrow aplasia. 11 (0.53%) patients had contraindications to vaccination including 3 (27.27%) egg allergy, 2 (18.18%) tuberculosis, 2 (18.18%) febril neutropenia ,2 (18.18%%) recent ischemic stroke (less than 20 days), 1 (9.09%) on treatment with Rituximab and 1 (9,09%) patient had a recent Guillan Barre Syndrom. (less than 6 weeks). 264 cancer patients ((12.89%) were included in the study of adherence to a vaccination campaign launched in medical oncology department of the hospital establishment DIDOUCHE Mourad, Constantine 189 (71.60%) patients were women and 75 (28.40%) patients were men. Different tumor localizations were noted. As a result, the influenza vaccination campaign coverage in our study was 13,17 % for all ages of cancer patients included and 48,86 % for those ≥ 65 years. Discussion: The influenza vaccination coverage was low among cancer patients. Influenza non-vaccination in the previous season was the strongest predictor of not receiving influenza vaccination in the current season. The main reasons for the low level of vaccination coverage rate that emerged in our study were having no-informations for indication to cancer patients (41,28%), fear of side effects (31,43%) getting medical treatment for cancer (chemotherapy, targeted therapy or immunotherapy ) (9,46%), lack of efficacy (9,09%), and no-need (8,71%). Nevertheless, after having informations and advice by medical oncologists, all patients stated that they will get vaccine next year. Conclusion: Vaccination against influenza in patients with cancer is a serious issue that presents many challenges, mainly in association with the immunocompromised state of these patients. Owing to disease and/or treatment-associated immunosuppression, patients with cancer are vulnerable to infectious diseases and are at high risk of developing infection- related complications, including those associated with influenza. Vaccination against common preventable diseases, including seasonal influenza, is therefore highly recommended in these patients.

  • Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial

    by K. Alsaleh, H. Al Zahwahry, A. Bounedjar, M. Oukkal, A. Saadeddine, H. Mahfouf, K. Bouzid, A. Bensalem, T. Filali, H. Abdel-Razeq, et al.

    Background The most prevalent subtype of breast cancer (BC) is luminal hormonal-positive breast cancer. The neoadjuvant chemotherapy regimens have side effects, emphasizing the need to identify new startegies. Objective Analyze the complete pathologic response (pCR) rate and overall response in a low-risk hormone-positive subset of patients receiving neoadjuvant hormone treatment (NAHT) with or without Palbociclib (a CDK4/CDK6 inhibitor) to boost NAHT effectiveness. Materials and methods Based on the upfront 21-gene Oncotype DX or low-risk Breast Recurrence Score assay (RS™), the SAFIA trial is designed as a prospective multicenter international, double-blind neoadjuvant phase-III trial that selects operable with luminal BC patients that are HER2-negative for the induction hormonal therapy with Fulvestrant 500 mg ± Goserelin (F/G) followed by randomization of responding patients to palbociclib versus placebo. The pCR rate served as the study’s main outcome, while the secondary endpoint was a clinical benefit. Results Of the 354 patients enrolled, 253 initially responded and were randomized to either F/G fulvestrant with palbociclib or placebo. Two hundred twenty-nine were eligible for the evaluation of the pathologic response. No statistically significant changes were observed in the pCR rates for the patients treated with the F/G therapy with placebo or palbociclib (7% versus 2%, respectively) per the Chevallier classification (Class1 + Class2) (p = 0.1464) and 3% versus 10% assessed per Sataloff Classification (TA, NA/NB) (p = 0.3108). Palbociclib did not increase the rate of complete pathological response. Conclusion Neoadjuvant hormonal therapy is feasible in a selected population with a low RS score of < 31 Clinical trial NCT03447132.


  • Open Access

    Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay—Results From the SAFIA Phase III Trial

    by Khalid AlSaleh, Heba Al Zahwahry, Adda Bounedjar, Mohammed Oukkal, Ahmed Saadeddine, Hassen Mahfouf, Kamel Bouzid, Assia Bensalem, Taha Filali, Hikmat Abdel-Razeq, et al.

    PURPOSE: Luminal, human epidermal growth factor receptor 2–negative breast cancer represents the most common subtype of breast malignancies. Neoadjuvant strategies of operable breast cancer are mostly based on chemotherapy, whereas it is not completely understood which patients might benefit from neoadjuvant hormone therapy (NAHT). MATERIALS AND METHODS: The SAFIA trial is a prospective multicenter, international, double-blind, neoadjuvant phase III trial, using upfront 21-gene Oncotype DX Breast Recurrence Score assay (recurrence score [RS] < 31) to select operable luminal human epidermal growth factor receptor 2–negative patients, for induction hormonal therapy HT (fulvestrant 500 mg with or without goserelin) before randomly assigning responding patients to fulvestrant 500 mg (with or without goserelin) plus either palbociclib (cyclin-dependent kinase 4/6 inhibitor) or placebo. The objectives of this interim analysis were to assess the feasibility of upfront RS determination on core biopsies in the Middle-East and North Africa region and evaluate the efficacy of induction NAHT in patients with an RS < 31. RESULTS: At the time of this interim analysis, 258 patients with relative risk were accrued, including 202 patients (RS < 31% to 78.3%) treated with induction NAHT and 182 patients evaluable so far for response. The feasibility of performing the Oncotype DX assays on core biopsy specimens was optimal in 96.4% of cases. Overall, 93.4% of patients showed hormone sensitivity and no difference in NAHT efficacy was noticed between RS 0-10, 11-25, and 26-30. Interestingly, patients with high RS (26-30) showed a trend toward a higher major response rate ( P = .05). CONCLUSION: The upfront 21-gene assay performed on biopsies is feasible in our population and has allowed us to select patients with high hormone sensitivity (RS < 31). This approach could be an alternative to upfront surgery without significant risk of progression, particularly during pandemic times.


  • 1579P Burnout among oncology professionals in the Middle East and North Africa (MENA)

    by A.M. Abusanad, A. Bensalem, E. Shash, L.Y.I. Mula-Hussain, Z. Benbrahim, S. Khatib, N. Abdelhafiz, J. Ansari, H. Jradi, K. Alkattan, et al.


  • Gemcitabine in metastatic breast cancer

    by A. Bensalem, K. Bouzid

    10735 Background: Gemcitabine (GEM) has shown efficacy in metastatic breast cancer (MBC). We conducted studies with GEM-based regimens to assess the efficacy and toxicity of GEM combined with other drugs in MBC. GEM was combined with docetaxel (DXL) in pre-treated MBC with an anthracycline-based regimen and GEM was combined with doxorubicin (DXR) in chemonaive patients (pts) with MBC. The studies’ objectives were to show clinically relevant hematologic toxicity and response rates among pts treated with GEM-DXL either in combination in pre-treated pts with anthracycline regimen or GEM-DXR in chemonaive pts with MBC to assess the efficacy of GEM in MBC either in neoadjuvant or first-line treatment. Methods: For GEM-DXL: 42 pts were enrolled; GEM: 1250 mg /m2 D1 & D8, DXL: 75 mg /m2 D1, every 21 days with classical premedication for DXL. For GEM-DXR: 51 pts were enrolled; GEM: 1250 mg /m2 D1 & D 8, DXR: 25 mg/m2 D1 & D8, every 21 days. Results: See table below. In the GEM-DXR group, surgery was performed in 30 pts, and 13 (43.2%) had histologically complete response. The median TTP in this group was 13.3 months (range, 2–53). Conclusions: GEM in MBC is very efficient and produced an interesting objective response and clinical benefit. This activity is consistent in either chemonaive pts or in pts with relapsing breast cancer. No significant financial relationships to disclose.